Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

Trial Profile

A Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 107 Radikal Therapeutics (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BEDROC
  • Sponsors Douglas Pharmaceuticals
  • Most Recent Events

    • 19 Nov 2019 Planned End Date changed from 31 Jul 2020 to 8 Mar 2021.
    • 04 Jun 2019 Planned End Date changed from 6 Mar 2020 to 31 Jul 2020.
    • 04 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 20 May 2019 to 10 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top